Remove news biopharma-news
article thumbnail

STAT+: Biotech startups post strongest financing numbers in two years

STAT

Venture-backed biopharma companies raised $6.8 That’s big news for an industry that has been icy for the last three years, once the attention the Covid pandemic brought to drug companies began to fade. billion in the first three months of the year, according to early data compiled by HSBC.

347
347
article thumbnail

New data on liquid biopsy for colorectal cancer detection still underwhelms

STAT

Today we talk about how biopharma plans to harness AI for clinical trial design, why two experts think Medicare ought to cover the costly GLP-1 drugs, and what news from Roivant means for its business strategy. Want to stay on top of the science and politics driving biotech today?  Read the rest…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Yes, biopharma still has a reputation problem. These leaders are looking for solutions

PharmaVoice

Negative news is breaking down the public’s perception of the biopharma industry — but leaders around the industry have some ideas to fix it.

243
243
article thumbnail

Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters

STAT

Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. We also break down the rest of the week’s biggest news in biopharma, including some billion-dollar deals and the retirement of perhaps the most storied executive in the business.

Vaccines 235
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Share the news with us, and we’ll share it with others.   This time around, we note that Zenas BioPharma hired Tanya Fischer as head of R&D and chief medical officer. Promoted a rising star? Finally solved that hard-to-fill spot?   That’s right. Send

259
259
article thumbnail

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

STAT

Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes it’s the biggest threat to the biopharma industry in 50 years. Bernie Sanders has in his sights next. Read the rest…

213
213
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Share the news with us, and we’ll share it with others.  That’s Previously, he worked was founder and chief scientific officer at Xeris Biopharma. Promoted a rising star? Finally solved that hard-to-fill spot?  That’s right. Send Don’t be shy.

219
219